HALO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HALO is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The stock has supportive analyst sentiment and solid revenue growth, but the current technical setup is weak, options sentiment is only moderately bullish, and latest earnings show profitability pressure. Since the user wants a direct answer and is not waiting for a perfect entry, my view is to hold off for now rather than buy immediately.
The short-term trend is bearish. MACD histogram is negative and still worsening, which signals downside momentum. RSI_6 at 31.571 is near oversold but not yet a strong reversal confirmation. Moving averages are also bearish with SMA_200 > SMA_20 > SMA_5, showing the stock is below its stronger trend structure. Pre-market price is 64.2, slightly above current option-tracked price of 63.66, and the stock is hovering near support at 63.444; losing that could expose downside toward 61.621. Overall, the chart does not support an immediate long entry.
["Analysts remain broadly constructive, with multiple target increases in April and February.", "Morgan Stanley and H.C. Wainwright both reiterated bullish ratings and raised targets to the mid-90s.", "Revenue in the latest reported quarter grew 51.6% YoY, showing strong top-line expansion.", "Upcoming Q1 2026 results on May 11, 2026 could act as a near-term catalyst.", "New CFO appointment may improve financial discipline and investor confidence."]
["Latest quarter showed a sharp net loss and negative EPS despite strong revenue growth.", "Gross margin declined year over year.", "Technical trend is bearish with negative MACD and weak moving-average structure.", "Hedge funds have been selling heavily, with selling up sharply last quarter.", "No recent insider buying trend and no recent congress trading activity to support the name."]
In Q4 2025, Halozyme posted revenue of $451.8M, up 51.6% year over year, which is a strong growth signal. However, profitability weakened materially: net income fell to -$141.6M and EPS dropped to -1.2, both sharply worse than the prior year. Gross margin also slipped to 77.39%. The latest quarter season is Q4 2025, and the key takeaway is strong growth but weaker earnings quality.
Analyst sentiment is positive and improving. H.C. Wainwright raised its target to $95 and kept Buy on April 29, 2026. Morgan Stanley raised its target to $96 and kept Overweight on April 21, 2026. Earlier in February, Benchmark raised its target to $90 and Morgan Stanley raised to $94 after strong Q4 results, while Wells Fargo stayed neutral at Equal Weight with a $75 target. Overall, Wall Street is constructive, but the more cautious view is that long-term upside depends on sustained royalty momentum and next-generation technology progress.
